Share on LinkedInShare on LinkedIn

ARTICLE · 17 JUNE 2016

Life Sciences Issues In Corporate Transactions – Part 2

In the second part to 'Life Sciences issues in corporate transactions' Colin McCall discusses the development cycle and the patent cliff and other matters important to the life science sector...

United KingdomIntellectual Property

In the second part to 'Life Sciences issues in corporate transactions', published in the January edition of Synapse, Colin McCall discusses the development cycle and the patent cliff and other matters important to the life science sector, including biosimilars, orphan medicines, parallel imports and compulsory licences.

THE DEVELOPMENT CYCLE AND THE PATENT CLIFF

Intellectual property protection is vital to maximising the benefit of R&D in the life sciences. Technological improvements, especially when embodied in commercial products, tend to be fairly transparent and therefore available to potential competitors. Such competitors can therefore acquire knowledge about new medicinal products within a reasonably short period of time and with a relatively modest R&D effort of their own.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from